http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 09 Mar 2026 08:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html <p align="center"><em>Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm</em></p> <p align="center"><em>STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as an endpoint to support accelerated approval pathway </em></p> <p>RICHMOND, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html Mon, 09 Mar 2026 08:05:00 -0400 A.06822034 A.31066700 A.39599018 A.50213784 O.00180660 O.08407916 O.20026344 O.22422661 SGMO http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html <p align="center"><em>Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm</em></p> <p align="center"><em>STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as an endpoint to support accelerated approval pathway </em></p> <p>RICHMOND, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html Mon, 09 Mar 2026 08:05:00 -0400 A.06822034 A.31066700 A.39599018 A.50213784 O.00180660 O.08407916 O.20026344 O.22422661 SGMO http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html <p align="center"><em>Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm</em></p> <p align="center"><em>STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as an endpoint to support accelerated approval pathway </em></p> <p>RICHMOND, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html Mon, 09 Mar 2026 08:05:00 -0400 A.06822034 A.31066700 A.39599018 A.50213784 O.00180660 O.08407916 O.20026344 O.22422661 SGMO http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html <p align="center"><em>Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm</em></p> <p align="center"><em>STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as an endpoint to support accelerated approval pathway </em></p> <p>RICHMOND, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html Mon, 09 Mar 2026 08:05:00 -0400 A.06822034 A.31066700 A.39599018 A.50213784 O.00180660 O.08407916 O.20026344 O.22422661 SGMO http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html <p align="center"><em>Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm</em></p> <p align="center"><em>STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as an endpoint to support accelerated approval pathway </em></p> <p>RICHMOND, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html Mon, 09 Mar 2026 08:05:00 -0400 A.06822034 A.31066700 A.39599018 A.50213784 O.00180660 O.08407916 O.20026344 O.22422661 SGMO http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html <p align="center"><em>Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm</em></p> <p align="center"><em>STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as an endpoint to support accelerated approval pathway </em></p> <p>RICHMOND, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html Mon, 09 Mar 2026 08:05:00 -0400 A.06822034 A.31066700 A.39599018 A.50213784 O.00180660 O.08407916 O.20026344 O.22422661 SGMO http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html <p align="center"><em>Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm</em></p> <p align="center"><em>STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as an endpoint to support accelerated approval pathway </em></p> <p>RICHMOND, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html Mon, 09 Mar 2026 08:05:00 -0400 A.06822034 A.31066700 A.39599018 A.50213784 O.00180660 O.08407916 O.20026344 O.22422661 SGMO http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html <p align="center"><em>Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm</em></p> <p align="center"><em>STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as an endpoint to support accelerated approval pathway </em></p> <p>RICHMOND, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html Mon, 09 Mar 2026 08:05:00 -0400 A.06822034 A.31066700 A.39599018 A.50213784 O.00180660 O.08407916 O.20026344 O.22422661 SGMO http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html <p align="center"><em>Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm</em></p> <p align="center"><em>STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as an endpoint to support accelerated approval pathway </em></p> <p>RICHMOND, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced http://www.streetinsider.com/Press+Releases/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html Mon, 09 Mar 2026 08:05:00 -0400 A.06822034 A.31066700 A.39599018 A.50213784 O.00180660 O.08407916 O.20026344 O.22422661 SGMO http://www.streetinsider.com/Globe+Newswire/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html <p align="center"><em>Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm</em></p> <p align="center"><em>STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as an endpoint to support accelerated approval pathway </em></p> <p>RICHMOND, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced http://www.streetinsider.com/Globe+Newswire/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html Mon, 09 Mar 2026 08:05:00 -0400 A.06822034 A.31066700 A.39599018 A.50213784 O.00180660 O.08407916 O.20026344 O.22422661 SGMO http://www.streetinsider.com/Globe+Newswire/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html <p align="center"><em>Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm</em></p> <p align="center"><em>STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as an endpoint to support accelerated approval pathway </em></p> <p>RICHMOND, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced http://www.streetinsider.com/Globe+Newswire/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html Mon, 09 Mar 2026 08:05:00 -0400 A.06822034 A.31066700 A.39599018 A.50213784 O.00180660 O.08407916 O.20026344 O.22422661 SGMO http://www.streetinsider.com/Globe+Newswire/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html <p align="center"><em>Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm</em></p> <p align="center"><em>STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as an endpoint to support accelerated approval pathway </em></p> <p>RICHMOND, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced http://www.streetinsider.com/Globe+Newswire/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html Mon, 09 Mar 2026 08:05:00 -0400 A.06822034 A.31066700 A.39599018 A.50213784 O.00180660 O.08407916 O.20026344 O.22422661 SGMO http://www.streetinsider.com/Globe+Newswire/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html <p align="center"><em>Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm</em></p> <p align="center"><em>STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as an endpoint to support accelerated approval pathway </em></p> <p>RICHMOND, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced http://www.streetinsider.com/Globe+Newswire/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html Mon, 09 Mar 2026 08:05:00 -0400 A.06822034 A.31066700 A.39599018 A.50213784 O.00180660 O.08407916 O.20026344 O.22422661 SGMO http://www.streetinsider.com/Globe+Newswire/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html <p align="center"><em>Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm</em></p> <p align="center"><em>STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as an endpoint to support accelerated approval pathway </em></p> <p>RICHMOND, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced http://www.streetinsider.com/Globe+Newswire/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html Mon, 09 Mar 2026 08:05:00 -0400 A.06822034 A.31066700 A.39599018 A.50213784 O.00180660 O.08407916 O.20026344 O.22422661 SGMO http://www.streetinsider.com/Globe+Newswire/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html <p align="center"><em>Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm</em></p> <p align="center"><em>STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as an endpoint to support accelerated approval pathway </em></p> <p>RICHMOND, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced http://www.streetinsider.com/Globe+Newswire/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html Mon, 09 Mar 2026 08:05:00 -0400 A.06822034 A.31066700 A.39599018 A.50213784 O.00180660 O.08407916 O.20026344 O.22422661 SGMO http://www.streetinsider.com/Globe+Newswire/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html <p align="center"><em>Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm</em></p> <p align="center"><em>STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as an endpoint to support accelerated approval pathway </em></p> <p>RICHMOND, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced http://www.streetinsider.com/Globe+Newswire/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html Mon, 09 Mar 2026 08:05:00 -0400 A.06822034 A.31066700 A.39599018 A.50213784 O.00180660 O.08407916 O.20026344 O.22422661 SGMO http://www.streetinsider.com/Globe+Newswire/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html <p align="center"><em>Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm</em></p> <p align="center"><em>STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as an endpoint to support accelerated approval pathway </em></p> <p>RICHMOND, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced http://www.streetinsider.com/Globe+Newswire/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html Mon, 09 Mar 2026 08:05:00 -0400 A.06822034 A.31066700 A.39599018 A.50213784 O.00180660 O.08407916 O.20026344 O.22422661 SGMO http://www.streetinsider.com/Globe+Newswire/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html <p align="center"><em>Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally shift Fabry treatment paradigm</em></p> <p align="center"><em>STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as an endpoint to support accelerated approval pathway </em></p> <p>RICHMOND, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced http://www.streetinsider.com/Globe+Newswire/Sangamo+Therapeutics+Advances+Rolling+Submission+of+BLA+to+U.S.+FDA+for+ST-920+in+Fabry+Disease/26129238.html Mon, 09 Mar 2026 08:05:00 -0400 A.06822034 A.31066700 A.39599018 A.50213784 O.00180660 O.08407916 O.20026344 O.22422661 SGMO http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SANGAMO+THERAPEUTICS%2C+++++For%3A+Feb+24++Filed+by%3A+Davis+Gregory+D/26073755.html si-local-file:///var/storage/secattach/20260226/26073755.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SANGAMO+THERAPEUTICS%2C+++++For%3A+Feb+24++Filed+by%3A+Davis+Gregory+D/26073755.html Thu, 26 Feb 2026 21:40:00 -0400 O.00180660 SGMO http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SANGAMO+THERAPEUTICS%2C+++++For%3A+Feb+24++Filed+by%3A+Davis+Gregory+D/26073755.html si-local-file:///var/storage/secattach/20260226/26073755.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SANGAMO+THERAPEUTICS%2C+++++For%3A+Feb+24++Filed+by%3A+Davis+Gregory+D/26073755.html Thu, 26 Feb 2026 21:40:00 -0400 O.00180660 SGMO http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SANGAMO+THERAPEUTICS%2C+++++For%3A+Feb+24++Filed+by%3A+Willoughby+Scott+B./26073756.html si-local-file:///var/storage/secattach/20260226/26073756.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SANGAMO+THERAPEUTICS%2C+++++For%3A+Feb+24++Filed+by%3A+Willoughby+Scott+B./26073756.html Thu, 26 Feb 2026 21:40:00 -0400 O.00180660 SGMO http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SANGAMO+THERAPEUTICS%2C+++++For%3A+Feb+24++Filed+by%3A+Willoughby+Scott+B./26073756.html si-local-file:///var/storage/secattach/20260226/26073756.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SANGAMO+THERAPEUTICS%2C+++++For%3A+Feb+24++Filed+by%3A+Willoughby+Scott+B./26073756.html Thu, 26 Feb 2026 21:40:00 -0400 O.00180660 SGMO http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SANGAMO+THERAPEUTICS%2C+++++For%3A+Feb+24++Filed+by%3A+Jain+Nikunj/26073757.html si-local-file:///var/storage/secattach/20260226/26073757.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SANGAMO+THERAPEUTICS%2C+++++For%3A+Feb+24++Filed+by%3A+Jain+Nikunj/26073757.html Thu, 26 Feb 2026 21:40:00 -0400 O.00180660 SGMO http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SANGAMO+THERAPEUTICS%2C+++++For%3A+Feb+24++Filed+by%3A+Jain+Nikunj/26073757.html si-local-file:///var/storage/secattach/20260226/26073757.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SANGAMO+THERAPEUTICS%2C+++++For%3A+Feb+24++Filed+by%3A+Jain+Nikunj/26073757.html Thu, 26 Feb 2026 21:40:00 -0400 O.00180660 SGMO http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SANGAMO+THERAPEUTICS%2C+++++For%3A+Feb+24++Filed+by%3A+Dubois-Stringfellow+Nathalie/26073758.html si-local-file:///var/storage/secattach/20260226/26073758.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++SANGAMO+THERAPEUTICS%2C+++++For%3A+Feb+24++Filed+by%3A+Dubois-Stringfellow+Nathalie/26073758.html Thu, 26 Feb 2026 21:40:00 -0400 O.00180660 SGMO